Amy Mottl, MD
Enriched profileProfessor of Medicine, Division of Nephrology and Hypertension · University of North Carolina at Chapel Hill School of Medicine
Amy Mottl is Professor of Medicine, Division of Nephrology and Hypertension at University of North Carolina at Chapel Hill School of Medicine. OpenAlex indexes 214 publications with 4,469 citations (h-index 32); ClinicalTrials.gov lists 3 registered studies with this person as an investigator.
Data verified 17 Aug 2026
Overview
Updated 16 Oct 2026
Amy Mottl, MD, is Professor of Medicine, Division of Nephrology and Hypertension at University of North Carolina at Chapel Hill School of Medicine, Department of Medicine, Division of Nephrology and Hypertension. The public record shows 214 publications with 4,469 citations (h-index 32), centered on Chronic Kidney Disease and Diabetes, Renal Diseases and Glomerulopathies, Diabetes Treatment and Management. It also documents an investigator role on 3 registered clinical trials, industry payments reported by 10 companies, 3 NIH-funded awards (2012–2026).
- Most recent indexed publication: 2026 · Clinical journal of the American Society of Nephrology
- Top research focus: Chronic Kidney Disease and Diabetes
- 3 registered trials on ClinicalTrials.gov
- Open Payments reporting from 10 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 28 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 69.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 3 registered studies on ClinicalTrials.gov. The most recent:
- The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study
Sponsor: University of North Carolina, Chapel Hill
- Kidney Precision Medicine Project
Sponsor: Icahn School of Medicine at Mount Sinai
- Transformative Research in Diabetic Nephropathy
Sponsor: University of Pennsylvania
Industry payments
Updated 16 Oct 2026
10 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Otsuka Pharmaceutical Development & Commercialization, Inc.Program year20252 payments
- Novartis Pharmaceuticals CorporationProgram year20251 payment
- Fresenius USA Marketing, Inc.Program year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
62.1%Loop diuretic11%Furosemide100%Part D≥13 patientsCalcium channel blocker9.4%Amlodipine Besylate100%Part D<11 patients+ 8 more classes in this area
Metabolism & gastrointestinal
29.4%SGLT2 inhibitor12.9%Jardiance53%Farxiga48%Part D<11 patientsHydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme9.1%Fabrazyme100%Part D<11 patients+ 2 more classes in this area
Musculoskeletal
4.2%Xanthine oxidase inhibitor4.2%Allopurinol100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
3 NIH research awards on record, funded 2012–2026 per NIH RePORTER. The latest:
- The Impact of Diabetes on Patients with Glomerular Disease: CureGN-Diabetes
Univ of North Carolina Chapel Hill
FY2026$592,933R01DK126959 - Geographic and Environmental Representation in Kidney Precision Medicine
Univ of North Carolina Chapel Hill
FY2026$475,632U01DK133095 - Cardiovascular and Renal Protection with SGLT2 Inhibition in Kidney Transplant Recipients (RENAISSANCE)
University of Minnesota
FY2026$352,966U34DK141987
Congress activity
Updated 16 Oct 2026
16 congress contributions (2018–2025) across ADA per OpenAlex. The most recent:
- 1863-LB: The Confidence Trial—Efficacy/Safety of Combining Finerenone with Empagliflozin in People with Chronic Kidney Disease and Type 2 Diabetes
ADA Scientific Sessions
ADA2025Co-authorLate-breaking - 259-OR: Arterial Stiffness and Diabetes-Associated Complications in the SEARCH for Diabetes in Youth Study
ADA Scientific Sessions
ADA2023Co-authorOral - 102-OR: Association of Elevated Arterial Stiffness with Cardiac Target Organ Damage in Young Adults with Diabetes: The Search for Diabetes in Youth Study
ADA Scientific Sessions
ADA2022Co-authorOral
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Primary Glomerular Diseases in the Elderly: Clinical Features, Treatment Patterns, and Outcomes in the CureGN Cohort.
Clinical journal of the American Society of Nephrology
Article2026 - Percutaneous Native Kidney Biopsy Complications in Diabetic Patients in the TRIDENT Cohort.
Clinical journal of the American Society of Nephrology
Article2026 - The (Mis)interpretation of Hazard Ratios in Clinical Trials.
Journal of the American Society of Nephrology
Article2026 - Authors' Reply: Clarifying Crossover Interpretation and Volume-Signal Assessment in ASSIST.
Journal of the American Society of Nephrology
Article2026 - Safety and Synergy of Finerenone and Empagliflozin in Lowering Blood Pressure.
Hypertension (Dallas, Tex.
Article2026
Most-cited works
by citation count (OpenAlex)- 01
- 02Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 DiabetesArticle253 citations2025
- 03N-Acetylcysteine for the Prevention of Radiocontrast Induced NephropathyArticle238 citations2004
- 04
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/amy-mottl-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/profile/Amy-Mottl-2
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - LinkedIn
linkedin.com/in/amy-mottl-7b45b2a8
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
unckidneycenter.org/about/mottl.html
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unckidneycenter.org ↗ - Other
unckidneycenter.org/2018/10/asns-kidney-week-2018-selects-dr-amy-mottls-paper-for-best-of-session
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →unckidneycenter.org ↗ - Other
med.unc.edu/medicine/news/chairs-corner/podcast/polycystic-kidney-disease-pkd-with-dr-amy-mottl
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu ↗ - YouTube
youtube.com/watch
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
Albert Einstein College of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu ↗ - MPH in Epidemiology
UNC Gillings School of Global Public Health
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →asn-online.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →asn-online.org ↗
- Editorial Board Member
American Journal of Kidney Diseases
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →ajkd.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu ↗
- Fellow
American Society of Nephrology (FASN)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu ↗
Media & interviews
press, podcasts and appearances- Podcast guest
"Polycystic Kidney Disease (PKD) - with Dr. Amy Mottl," Chair's Corner (UNC Department of Medicine), interviewed by Dr. Ron Falk
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →med.unc.edu ↗ - Featured interview
"Managing CKD in the Face of a Growing Diabetes Epidemic, with Amy Mottl, MD," HCPLive
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →hcplive.com ↗ - Guest
ASN Kidney Week podcast (Day 2 recap episode, with Kirk Campbell and Precious McCowan)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →asn-online.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Bradley Gaynes, MD
University of North Carolina at Chapel Hill School of Medicine
Alan Hinderliter, MD
University of North Carolina at Chapel Hill School of Medicine
Christopher Sayed, MD
University of North Carolina at Chapel Hill School of Medicine
Howard Scher, MD
Memorial Sloan Kettering Cancer Center
Toni Choueiri, MD
Dana-Farber Cancer Institute
Robert Motzer, MD
Memorial Sloan Kettering Cancer Center
Fred Saad, MD
Centre hospitalier de l'Université de Montréal (CHUM)